New partnership with UpScript provides access to care and PoNS devices delivered to your doorstep
NEWTOWN, Pa., Jan. 03, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies (NASDAQ: HSDT) makes its innovative portable neuromodulation stimulator easily accessible to Americans with walking problems We have launched a new e-commerce site that will allow you to: (PoNS®). When combined with physiotherapist-supervised exercise therapy, the PoNS device improves gait disturbance in MS patients.
This is the first time Helius, a neurotech company focused on neurological health, has made PoNS available online through telemedicine. The UpScript platform allows a person with multiple sclerosis to have her PoNS device delivered directly to her doorstep. This can be a game-changer for people who have difficulty walking.
The site, accessible from ponstherapy.com, is enhanced through a new partnership with UpScript. UpScript is a leading telemedicine company focused on delivering medicines and devices directly to consumers. UpScript’s platform enables 1) online health assessments by qualified healthcare providers, 2) fulfillment of prescriptions required for PoNS Therapy™, and 3) direct delivery of his PoNS device to an eligible patient’s home in the United States. provide.
“People want to remove the barriers that keep them from doing their best, and we want to give them the tools and technology to help them achieve that goal. said Dane Andreeff, president and chief executive officer of Helius. “Our UpScript partnership simplifies and shortens the process of reaching out to healthcare providers and putting PoNS devices into the hands of those aspiring to improve their gait. It speaks to our commitment to helping patients who put their trust in us.”
While the ability to access quality healthcare providers and PoNS devices through telemedicine without leaving home is new, other key elements of PoNS therapy have not changed. Device purchasers should work with a trained physical therapist. During his first two weeks of treatment, these experts work face-to-face with the user, guiding them through therapeutic exercises designed to maximize the effectiveness of the device. For her next 12 weeks, the user continues treatment at home under the supervision of a therapist.
“People with walking difficulties often face many challenges, and leveraging cutting-edge neurological technologies that can improve their daily lives should not be one of them,” says Andreeff. says Mr. “With our new telemedicine partnership, the journey to walking better can now begin with just a few keystrokes. and we are committed to serving them.”
About Helius Medical Technologies
Helius Medical Technologies is a neurological disorders focused medical device field with non-implantable platform technology that amplifies the brain’s ability to compensate and promote neuroplasticity, improving the lives of people coping with neurological disorders. is a leading neurotech company. Our first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information, please visit www.heliusmedical.com.
About PoNS devices and PoNS therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device that includes a controller and mouthpiece that provides electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment for gait disturbance due to mild to moderate symptoms due to multiple sclerosis (“MS”) and is used as an adjunct to a supervised therapeutic exercise program. Patients over 22 years old by prescription only. Helius is pursuing her PoNS post-approval studies for MS through her recently launched Therapeutic Experience Program (TEP).
PoNS is also approved for sale in Canada for two indications. Used in conjunction with physical therapy. (ii) PoNS is approved for use as a short-term treatment (14 weeks) for gait disturbances due to mild and moderate symptoms due to MS and is used in combination with physical therapy; PoNS is also licensed for sale in Australia for short-term use by health care professionals as an adjunct to therapeutic exercise programs to improve balance and gait. For more information, please visit www.ponstherapy.com.
About UpScript Health
UpScriptHealth provides a fully compliant D2C Telehealth platform for pharmaceutical and consumer products companies. This unique platform enables convenient access to high-quality healthcare, including cutting-edge medicines. In 2002, UpScript became the first in the United States to obtain a license to generate prescriptions over the Internet through an online physician consultation. Since then, we have treated over 1 million of her patients in all 50 of her states. For more information, please visit www.UpScriptHealth.com.
Certain statements in this news release are not historical facts and constitute forward-looking statements or forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and the Canadian Securities Act. . All statements other than statements of historical fact contained in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by words such as “believe,” “continue,” “expect,” “will,” “goal,” “aim,” or similar expressions. Such forward-looking statements include, among other things, statements regarding the success of our telemedicine partnership with the UpScript Platform.
There can be no assurance that such statements will prove to be accurate, and actual results and future events may differ materially from those expressed or implied by such statements. Significant factors that could cause our forecasts to differ materially include our capital requirements to meet our business goals, the availability of funding, our ability to find additional sources of funding and the impact of the COVID-19 pandemic. , manufacturing, labor shortages and supply chain risks, our ability to train physical therapists to oversee the use of PoNS treatments, our ability to secure contracts with rehabilitation clinics, obtain national Medicare coverage, Our Ability to Get Reimbursed Coded PoNS devices to be covered by Medicare and Medicaid, built in-house commercial infrastructure, secured state distribution licenses, built commercial teams, key opinion leaders, Our ability to build relationships with neurology professionals, neurorehabilitation centers, market awareness of PoNS devices, future clinical trials and t clinical development processes, ongoing government regulations and other factors, and December 2021 Other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 and its quarterly reports March 31, 2022, June 2022. Form 10-Q for the quarter ended September 30, 2022, and other filings filed with the U.S. Securities and Exchange Commission and Canadian securities regulators, available at www.sec. I can do it. .gov or www.sedar.com.
Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release and the Company undertakes no obligation to update any forward-looking statements or that actual results may differ from such statements. We do not undertake any obligation to update any possible reasons. required by law.
Investor Information Inquiries
Lisa M. Wilson, In-Site Communications, Inc.